港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

592.468

+14.5352.51%

漲家數：21

跌家數：7

平家數：6

市盈率：- -

高：598.497

開：578.227

低：578.109

收：577.933

成交量：4,160.36萬

成交額：16.72億

市值：3,781.29億

流通市值：3,368.19億

資料載入中...

總覽新聞資訊

港股生物醫藥板塊漲幅居前，康方生物升逾5%，科倫博泰生物升逾4%

老虎资讯综合

快訊：恒指低開0.27% 科指跌0.68% 科網股走弱創新藥概念高開快手跌超9%

【券商聚焦】中信建投：醫療器械板塊拐點來臨，26年業績改善個股存在業績估值修復機會

雲頂新耀(01952)2025年股東淨虧損按年收窄71.4%

《業績》亞盛醫藥－Ｂ(06855.HK)去年虧損擴大至12.43億人民幣

阿斯达克财经

沛嘉醫療-B(09996.HK)：董事會董事長張一博士擬於公開市場繼續增持股份

亞盛醫藥-B(06855)雙引擎驅動高增長，耐立克銷售按年大增81%

雲頂新耀(01952)發布年度業績收益17.07億元按年大增141.51% 耐賦康®銷售驅動強勁增長

智通财经网

東阿阿膠副總裁李慶川辭職；默克擬收購美國生物技術公司Terns | 醫藥早參

每日经济新闻

康寧傑瑞製藥-B財年虧損1.139億元人民幣

康寧傑瑞製藥-B(09966)發布年度業績，年內虧損人民幣1.14億元按年盈轉虧

同源康醫藥-B(02410)將於2026年AACR年會上展示五個創新藥項目的研究成果

沛嘉醫療-B(09996)發布年度業績收入按年增長15.82%至7.13億元神經介入業務分部利潤按年大幅增長86.6%

沛嘉醫療-B：2026年或成集團神經介入業務全球化擴張的起點

李氏大藥廠(00950)：茵若颯取得國家藥監局批准

復星醫藥2025年報：收入417億，淨利增速21.7%，創新藥與境外收入佔比同步提升

楚天科技：子公司楚天智能機器人目前專注於醫藥、醫用、化妝品及技術同心圓等相關領域

兆科眼科-B(06622)公布2025年業績税後虧損約2.09億元按年收窄12%

Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income

歸創通橋(02190)3月25日耗資約189.24萬港元回購7.9萬股

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎證券,老虎證券開戶,老虎券商,老虎證券官網,老虎證券app,tigertrade老虎證券,股票,炒股,新加坡股票交易平臺,投資,投資理財","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/BK1574/news"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":592.46826,"timestamp":1774493287386,"preClose":577.93304,"halted":0,"volume":41603645,"delay":0,"changeRate":0.02515,"floatShares":0,"shares":0,"eps":0,"marketStatus":"交易中","change":14.535217,"latestTime":"03-26 10:48:08","open":578.2267,"high":598.49725,"low":578.109,"amount":1671936945,"amplitude":0.035278,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"午間休市","tradingStatus":4,"beginTime":1774497600000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1774488600000,1774497600000],[1774501200000,1774512000000]],"pbRate":5.179109,"peRate":-60.041027,"turnoverRate":0.001517,"increases":21,"decrements":7,"flats":5,"marketCap":378128763072,"floatMarketCap":336818962992},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":598.49725,"amplitude":0.035278,"preClose":577.93304,"low":578.109,"pbRate":"5.179109","latestPrice":592.46826,"volume":41603645,"delay":0,"open":578.2267,"prevYearClose":556.26263,"prevWeekClose":560.669,"prevMonthClose":553.496,"prevQuarterClose":556.263,"fiveDayClose":571.212,"twentyDayClose":537.703,"sixtyDayClose":574.89,"secType":"PLATE","market":"HK","turnoverRate":0.001517,"peRate":-60.041027,"marketCap":378128763072,"floatMarketCap":336818962992,"timestamp":1774493287386,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":21,"down":7,"flat":6},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"1112843274","title":"港股生物醫藥板塊漲幅居前，康方生物升逾5%，科倫博泰生物升逾4%","url":"https://stock-news.laohu8.com/highlight/detail?id=1112843274","media":"老虎资讯综合","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1112843274?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:54","pubTimestamp":1774490076,"startTime":"0","endTime":"0","summary":"3月26日，$生物(000504)$医药板块涨幅居前，$康方生物(09926)$涨超5%，$科伦博泰(06990)$生物涨超4%，$泰格医药(03347)$、$荣昌生物(09995)$涨超3%，$药明康德(02359)$、$君实生物(01877)$等个股跟涨","market":"us","thumbnail":"https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c","type":0,"news_type":0,"thumbnails":["https://static.tigerbbs.com/6ad7ed6b96b448ffcc5b5501b0dc346c"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":true,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0417516902.SGD","LU0348784397.USD","LU1961090484.USD","LU0348766576.USD","09926","02162","09995","BK4588","BK4581","LU2778985437.USD","LU1720050803.USD","01877","LU2476274308.USD","IE00B5MMRT66.SGD","BK1161","IE00BPRC5H50.USD","BK1574","LU0348783233.USD","LU0540923850.HKD","LU0348767384.USD","LU0417516738.SGD","BK4585","LU0634319403.HKD","LU2476274720.SGD","LU0348735423.USD","LU0561508036.HKD","LU2488822045.USD","LU2399975544.HKD","LU1794554557.SGD","LU0348827113.USD","IE00B543WZ88.USD","LU0348825331.USD","LU0417516571.SGD","03347"],"gpt_icon":0},{"id":"2622813298","title":"快訊：恒指低開0.27% 科指跌0.68% 科網股走弱 創新藥概念高開 快手跌超9%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622813298","media":"新浪港股","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622813298?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:20","pubTimestamp":1774488000,"startTime":"0","endTime":"0","summary":"热点栏目\n\n自选股\n数据中心\n行情中心\n资金流向\n模拟交易\n\n客户端\n\n\n　　美股周三表现向上，中东局势有缓和迹象，油价由高位回落，带动大市气氛，三大指数均录得升幅收市。美元先跌后回升，美国十年期债息回落至4.33厘水平，金价反复向好，油价先跌后回稳。\n　　今日港股三大指数集体低开，恒指开盘跌0.27%，报25267.16点，恒科指跌0.68%，国企指数跌0.41%。盘面上，科网股涨跌不一，京东涨超2%，快手跌超9%，哔哩哔哩跌超1%；创新药概念股活跃，乐普生物涨超6%；汽车股部分走弱，蔚来跌超2%。\n\n\n\n\n海量资讯、精准解读，尽在新浪财经APP\n\n责任编辑：郝欣煜","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/marketalerts/2026-03-26/doc-inhshnwy0334896.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["LU0211977185.USD","LU1251922891.USD","LU1720050803.USD","LU1303224171.USD","HSTECH","LU0359201885.HKD","LU0572944931.SGD","BK1610","BK1590","HHImain","LU0359201612.USD","LU1719994722.HKD","MCHmain","BK1161","LU0348766576.USD","81024","BK1591","LU0348767384.USD","01024","LU2097828474.EUR","LU0326950275.SGD","LU1794554557.SGD","LU0588546209.SGD","LU2097828714.EUR","LU0210526637.USD","BK1574","LU2097828631.EUR","BK1615","LU0456827905.SGD","BK1608","513600","LU0051755006.USD","LU1770034418.SGD","LU0140636845.USD","LU0593848301.USD","LU0327786744.USD","LU0244354667.USD","LU1188198961.HKD","LU0359202008.SGD","LU1023057109.AUD","LU2097828557.USD","LU0307460666.USD","BK1575","BK1095","LU0463099449.HKD","LU2097828805.USD","02833","HSI"],"gpt_icon":0},{"id":"2622818008","title":"【券商聚焦】中信建投：醫療器械板塊拐點來臨，26年業績改善個股存在業績估值修復機會","url":"https://stock-news.laohu8.com/highlight/detail?id=2622818008","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622818008?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:18","pubTimestamp":1774487918,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投表示，医疗器械板块拐点来临，26年业绩改善个股存在业绩估值修复机会。建议持续关注市场空间大、国产化率低的创新器械赛道，以及并购重组、脑机接口、AI医疗、手术机器人、外骨骼机器人等主题方向的投资机会。潜在催化较多的方向有望出现涨幅数倍的个股，未来AI医疗、脑机接口等也有望成为投资人重点关注的新科技方向。","market":"fut","thumbnail":"https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MjAwMmJhMzhlMzU2ODgyNzA0NzY4MTcyNA==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977292","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06826","BK1593","BK1574","601066","BK1571","BK1591","09997","BK1584","BK1502","BK1583","LU0173614495.USD","159883","01066","01302","BK1615","BK1142","BK1100","09996","BK1610","BK1600","02190","BK1222","02235","BK1515","BK1589","BK1585","BK1617","LU0287142896.SGD","BK1247","02252","BK1587","BK1501","BK1189","00853","BK1161","00241","BK0276"],"gpt_icon":0},{"id":"2622198889","title":"雲頂新耀(01952)2025年股東淨虧損按年收窄71.4%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622198889","media":"金吾财讯","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622198889?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 09:04","pubTimestamp":1774487064,"startTime":"0","endTime":"0","summary":"金吾财讯 | 云顶新耀(01952)公告发布，截至2025年12月31日止，公司母公司拥有人应占净亏损为2.98亿元(人民币，下同)，同比减亏71.4%，每股基本净亏损0.89元，同比减亏72.5%。期内，录得收益17.07亿元，同比增长1.41倍；毛利润11.82亿元，同比增长1.24倍。期内，集团研发开支5.11亿元，分销及销售开支7.81亿元，一般行政开支2.77亿元。","market":"us","thumbnail":"https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20210810/MGVkMTYyODU4OTM2NDU2Mg==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1977287","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1161","BK1574","01952","BK1583"],"gpt_icon":0},{"id":"2622886079","title":"《業績》亞盛醫藥－Ｂ(06855.HK)去年虧損擴大至12.43億人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2622886079","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622886079?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 08:52","pubTimestamp":1774486320,"startTime":"0","endTime":"0","summary":"亚盛医药－Ｂ(06855.HK) 公布截至去年12月底止全年业绩，营业额5.74亿元人民币(下同)，按年跌41.5%。亏损扩大至12.43亿元，上年同期蚀4.05亿元；每股亏损3.49元。不派末期息。(ca/w)(港股报价延迟最少十五分钟。沽空资料截至 2026-03-25 16:25。)过往派息公布日期派息事项派息内容2025/08/21中期业绩无派息2025/03/27末期业绩无派息2024/08/22中期业绩无派息2024/03/27末期业绩无派息AASTOCKS新闻","market":"other","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20191016100749692_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20191016100749692_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512620/latest-news/AAFN","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/NOW.1512620/latest-news/AAFN","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["MCNHmain","CYB","06855","BK1574","CNHmain","UCmain","MUCmain","BK1161"],"gpt_icon":0},{"id":"2622883271","title":"沛嘉醫療-B(09996.HK)：董事會董事長張一博士擬於公開市場繼續增持股份","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883271","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883271?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 07:37","pubTimestamp":1774481825,"startTime":"0","endTime":"0","summary":"格隆汇3月26日丨沛嘉医疗-B(09996.HK)发布公告，董事会获悉，执行董事、首席执行官兼董事会董事长张一博士(“张博士”)透过其所控制的公司，自2026年3月26日起拟于公开市场上继续购买公司股份。是次持股增加合共代价预期不超过1500万港元。\r\n\r\n　　经张博士告知，持股增加反映其对公司内在价值的认可，以及其对公司发展前景及增长潜力的坚定信心。张博士将不排除根据适用法律及法规于适当时候进一步增加其于公司持股的可能性。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260326/32098777.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1100","BK1574","159891","BK1583","09996"],"gpt_icon":0},{"id":"2622588314","title":"亞盛醫藥-B(06855)雙引擎驅動高增長，耐立克銷售按年大增81%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622588314","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622588314?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 07:28","pubTimestamp":1774481290,"startTime":"0","endTime":"0","summary":"3月26日，头部创新药企业亚盛医药发布2025年全年业绩。作为公司首款商业化产品，耐立克在2025年迎来医保落地后的首个完整销售年份，销售额实现显著增长，达到4.35亿元人民币，同比大幅增长81%。公司第二款产品、中国首个上市的国产原创Bcl-2抑制剂利生妥自2025年7月获批后快速放量，截至报告期末的5个月内实现销售额7058万元人民币。业绩增长由已上市的两大核心产品“双引擎”高效驱动。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419181.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"亚盛医药-B(06855)双引擎驱动高增长，耐立克销售同比大增81%","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["AAPG","BK1574","BK4139","06855","BK1161"],"gpt_icon":0},{"id":"2622883992","title":"雲頂新耀(01952)發布年度業績 收益17.07億元 按年大增141.51% 耐賦康®銷售驅動強勁增長","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883992","media":"智通财经网","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883992?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 07:23","pubTimestamp":1774481019,"startTime":"0","endTime":"0","summary":"智通财经APP讯，云顶新耀 发布截至2025年12月31日止年度业绩，集团收益人民币17.07亿元，同比增长141.51%;股东应占亏损2.98亿元;研发开支5.11亿元;毛利11.82亿元，同比增长124.32%。收益增加主要由于耐赋康在已商业化市场的销售额继续上升所致。在中国市场，将耐赋康纳入国家医保药品目录为关键的增长动力，以致截至2025年12月31日止年度的耐赋康收益大幅增加。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419180.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"2","news_top_title":"云顶新耀(01952)发布年度业绩 收益17.07亿元 同比大增141.51% 耐赋康®销售驱动强劲增长","news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"highlight_zhitongcaijin","symbols":["BK1574","BK1583","BK1161","01952"],"gpt_icon":0},{"id":"2622883390","title":"東阿阿膠副總裁李慶川辭職；默克擬收購美國生物技術公司Terns | 醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2622883390","media":"每日经济新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622883390?lang=zh_tw&edition=fundamental","pubTime":"2026-03-26 07:06","pubTimestamp":1774479983,"startTime":"0","endTime":"0","summary":"丨2026年3月26日星期四丨NO.1东阿阿胶副总裁李庆川辞职3月25日，东阿阿胶发布公告，称董事会近日收到李庆川提交的书面辞职报告，由于工作变动原因，李庆川申请辞去公司副总裁职务。辞职后，李庆川将担任公司党委副书记职务。截至公告日，李庆川持有公司20639股限制性股票，原定任期届满之日为2027年8月6日。点评：公司表示该项辞职不会影响公司相关工作的正常进行。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202603263684586713.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202603263684586713.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["LU0070302665.USD","LU2361044865.SGD","LU1291159041.SGD","LU1116320737.USD","SG9999014559.SGD","SG9999002232.USD","LU2089984988.USD","LU2468319806.SGD","MRK","BK4588","LU0006306889.USD","BK4585","LU2125154778.USD","BK4516","688197","LU2324357040.USD","SG9999002224.SGD","BK1574","IE00B1BXHZ80.USD","LU0861579265.USD","BK0183","SG9999001440.SGD","SG9999014575.USD","LU0985320562.USD","LU2106854487.HKD","LU1934455863.HKD","BK4550","IE00BN8TJ469.HKD","LU0203347892.USD","IE0009355771.USD","LU1929549753.HKD","BK1161","BK0028","IE00BLSP4239.USD","LU2361045086.USD","LU1201861249.SGD","LU0130102774.USD","LU0965509283.SGD","LU2023250504.SGD","LU0965509101.SGD","BK0188","LU1023059063.AUD","LU2023250843.SGD","LU0868494708.USD","LU0289739699.SGD","LU0942090050.USD","LU0477156953.USD","LU0266013472.USD","000423","LU1699723380.USD","LU1066051498.USD","IE0002141913.USD","LU0058720904.USD","IE00B4R5TH58.HKD","IE00BBT3K403.USD","LU1162221912.USD","BK4533","LU1989772923.USD","LU0648001328.SGD","IE00BFTCPJ56.SGD","LU1983299246.USD","SG9999013999.USD","LU0965508806.USD","LU2361044949.HKD","LU0320765489.SGD","LU0868494617.USD","LU0965509010.AUD","LU1093756168.USD","LU1037948897.HKD","LU0106261372.USD","SG9999014567.USD","SG9999001176.SGD","IE00BLSP4452.SGD","BK4534","LU1430594728.SGD","LU0211331839.USD","BK4559","LU2461242641.AUD","SG9999014542.SGD","LU1116320901.HKD","LU0203345920.USD","BK1515","LU1934455194.USD","LU1934455277.USD","LU2360032135.SGD","BK0175","LU0208291251.USD","IE00BSNM7G36.USD","SGXZ57979304.SGD","LU1066051811.HKD","SG9999001176.USD","LU0265550359.USD","BK0187","LU1066053197.SGD","LU1974910355.USD","LU0234572021.USD","LU0238689110.USD","BK0239","LU1057294990.SGD","LU0432979614.USD","LU1061106388.HKD","LU2112291526.USD","LU0122379950.USD","LU1571399168.USD","LU1585245621.USD","LU1035773651.USD","LU2125154935.USD","600812","SG9999014674.SGD","SG9999015341.SGD","BK4007","LU1917777945.USD","IE00BJJMRZ35.SGD","LU0265550946.USD","LU1069347547.HKD","IE00B2B36J28.USD","09939","LU1941712264.USD","LU0098860793.USD","LU1037948541.HKD","LU0320765646.SGD","LU1989772840.SGD","LU1989771016.USD","LU0130517989.USD","LU1066051225.USD","LU0980610538.SGD","BK0196","LU1093756325.SGD","SG9999015358.SGD","BK0010","IE00BJT1NW94.SGD","IE000M9KFDE8.USD","LU1941712348.USD"],"gpt_icon":0},{"id":"1153293212","title":"康寧傑瑞製藥-B財年虧損1.139億元人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=1153293212","media":"投资观察","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1153293212?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 23:41","pubTimestamp":1774453268,"startTime":"0","endTime":"0","summary":"康宁杰瑞制药-B（9966.HK）公布最新财年业绩，录得净亏损达1.139亿元人民币。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","09966","BK1161"],"gpt_icon":0},{"id":"2622841070","title":"康寧傑瑞製藥-B(09966)發布年度業績，年內虧損人民幣1.14億元 按年盈轉虧","url":"https://stock-news.laohu8.com/highlight/detail?id=2622841070","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622841070?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 23:14","pubTimestamp":1774451655,"startTime":"0","endTime":"0","summary":"智通财经APP讯，康宁杰瑞制药-B(09966)发布截至2025年12月31日止年度业绩，该公司取得收入人民币5.66亿元，同比减少11.54%;年内亏损人民币1.14亿元，同比盈转亏;每股亏损人民币0.12元。公告称，研发开支由截至2024年12月31日止年度的人民币4.04亿元增加至截至2025年12月31日止年度的人民币5.72亿元，主要由于(i)正在进行的临床试验数目增加;(ii)公司临床研究规模的扩大;及(iii)公司候选药物的临床试验进展。下表列载于所示年度按性质划分的研发开支明细。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419120.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-2","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["09966","BK1574","UCmain","MCNHmain","CNHmain","CYB","MUCmain","BK1161"],"gpt_icon":0},{"id":"2622072086","title":"同源康醫藥-B(02410)將於2026年AACR年會上展示五個創新藥項目的研究成果","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072086","media":"智通财经","labels":["conferences"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072086?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 22:42","pubTimestamp":1774449755,"startTime":"0","endTime":"0","summary":"智通财经APP讯，同源康医药-B(02410)发布公告，本公司将于2026年美国癌症研究协会(AACR)年会壁报环节展示TY-0609(CDK4抑制剂)、TY-2699a(CDK7抑制剂 )、 TY-2719(EGFR/FAK(PROTAC)抑制剂)、PI3Kα(PI3Kα抑制剂)、TY-1054 (YAP-TEAD抑制剂)五个在研创新药项目的研究进展和成果，此次展示的五个项目均为本公司自主研发的抗肿瘤小分子创新候选药物。本届AACR年会将于2026 年4月17日至22日在美国圣地亚哥举行，本公司参会壁报将分别于4月19日至4月 21日展示。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419089.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"conferences","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1515","09939","BK1574","159992","06978","02410","BK1161","159938"],"gpt_icon":0},{"id":"2622072988","title":"沛嘉醫療-B(09996)發布年度業績 收入按年增長15.82%至7.13億元 神經介入業務分部利潤按年大幅增長86.6%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622072988","media":"智通财经","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622072988?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 22:23","pubTimestamp":1774448601,"startTime":"0","endTime":"0","summary":"智通财经APP讯，沛嘉医疗-B 发布截至2025年12月31日止年度业绩，该集团取得收入7.13亿元，同比增长15.82%;股东应占亏损同比收窄10.28%;每股基本亏损0.31元。报告期内，集团实现收入人民币7.13亿元，同比增长15.82%。神经介入业务分部利润同比增长86.6%至人民币9720万元，而经导管瓣膜治疗业务分部亏损同比收窄20.2%至人民币2.16亿元。若剔除前沿技术业务组成实体应占的亏损，集团年度经调整亏损将为人民币1.11亿元，同比收窄44.1%。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419071.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","159891","BK1100","09996"],"gpt_icon":0},{"id":"1194672043","title":"沛嘉醫療-B：2026年或成集團神經介入業務全球化擴張的起點","url":"https://stock-news.laohu8.com/highlight/detail?id=1194672043","media":"美股速递","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1194672043?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 22:15","pubTimestamp":1774448130,"startTime":"0","endTime":"0","summary":"沛嘉医疗-B预计，2026年将成为集团在神经介入业务领域迈向全球市场布局的初步阶段。","market":"us","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1100","BK1583","BK1574","09996"],"gpt_icon":0},{"id":"2622071591","title":"李氏大藥廠(00950)：茵若颯取得國家藥監局批准","url":"https://stock-news.laohu8.com/highlight/detail?id=2622071591","media":"智通财经","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622071591?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 21:37","pubTimestamp":1774445826,"startTime":"0","endTime":"0","summary":"智通财经APP讯，李氏大药厂(00950)发布公告，于2026年3月17日，中国国家药品监督管理局(国家药监局)已批准茵若飒(由Cosette Pharmaceuticals拥有并已授予李氏大药厂许可)用于治疗具有中重度症状(不包括泌尿系症状)的绝经后女性外阴阴道萎缩。继本公司全资附属公司兆科药业(合肥)有限公司进行的第III期、多中心、随机、双盲、平行对照临床试验成功完成后，是次获批标志着一个重要的里程碑。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1419040.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["06622","BK1574","BK1191","BK1587","BK1583","00950"],"gpt_icon":0},{"id":"2622074818","title":"復星醫藥2025年報：收入417億，淨利增速21.7%，創新藥與境外收入佔比同步提升","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074818","media":"IPO早知道","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074818?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 21:32","pubTimestamp":1774445520,"startTime":"0","endTime":"0","summary":"报告期内，经营活动产生的现金流量净额为52.13亿元，同比增长16.45%，增长主要系对外授权收入增加所致。创新药管线：研发投入转向商业兑现的效率提升复星医药2025年研发总投入达59.13亿元，同比增长6.46%，其中创新药品相关研发投入43.03亿元，同比大增15.98%，占研发总投入的72.77%，占比同比提升5.97个百分点。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/hk/2026-03-25/doc-inhsfmmn0790711.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["06978","BK0183","BK0028","BK0096","BK0175","02196","BK1515","BK1161","BK0196","600196","BK0012","BK1574","BK1191","BK0239","BK0187","BK0060","159992","BK1593","BK0188"],"gpt_icon":0},{"id":"2622074580","title":"楚天科技：子公司楚天智能機器人目前專注於醫藥、醫用、化妝品及技術同心圓等相關領域","url":"https://stock-news.laohu8.com/highlight/detail?id=2622074580","media":"证券日报 ","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622074580?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 21:31","pubTimestamp":1774445460,"startTime":"0","endTime":"0","summary":"证券日报网讯 3月25日，楚天科技在互动平台回答投资者提问时表示，公司专注于为全球医药客户提供自动化、智能化整体解决方案，相关业务及技术拓展围绕着技术同心圆、客户同心圆和产品同心圆展开。子公司楚天智能机器人目前同样专注于医药、医用、化妆品及技术同心圆等相关领域，工业机器人系用于公司产品中，提升产品整体性能。目前占公司业务占比较小，请投资者注意投资风险。（文章来源：证券日报）\n\n\n海量资讯、精准解读，尽在新浪财经APP","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"sina","url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-25/doc-inhsfmmn0792719.shtml","rn_cache_url":null,"customStyle":"body{padding-top:10px;}.art_tit_h1{#titleStyle#}a{#lv2TextColor#}.art_time, .art_cite{#sourceStyle#;} .art_cite{margin-left: 3px;}","selectors":".module-article, article","filters":"header, .voice2, .tags, #norm_qrcode_link_auto, .unfold-box, .action","directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/relnews/cn/2026-03-25/doc-inhsfmmn0792719.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["09939","BK0061","BK1515","300358","ROBO","BK0028","BK1161","159938","BK0251","BK1574","BK0077"],"gpt_icon":0},{"id":"2622078438","title":"兆科眼科-B(06622)公布2025年業績 税後虧損約2.09億元 按年收窄12%","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078438","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078438?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:46","pubTimestamp":1774439191,"startTime":"0","endTime":"0","summary":"智通财经APP讯，兆科眼科-B(06622)公布2025年业绩，收益3197.4万元，同比减少53.88%;税后亏损约2.09亿元，同比收窄12%。公告称，亏损减少主要源于集团继续严格控制行政费用及销售及分销开支，反映年内成本控制有所加强及营运架构效率提升。此外，研发开支随着若干主要开发里程碑达成而有所减少，并无如上一年度产生非经常性开支亦进一步推动改善。尽管并无如上一年度取得一次性的许可收入，且2025年利率下调令银行利息收入减少，惟集团取得的年内亏损仍然实质收窄。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418929.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1583","BK1191","06622","BK1587"],"gpt_icon":0},{"id":"2622078184","title":"Zhaoke Ophthalmology FY2025; revenue drops to CNY 32 million due to lower one-off license income","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078184","media":"Reuters","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078184?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:43","pubTimestamp":1774439016,"startTime":"0","endTime":"0","summary":"Zhaoke Ophthalmology reported regulatory milestones that could expand its near-term commercial portfolio, led by three flagship assets positioned for large ophthalmology markets in China and internationally.In China, 国家药监局 accepted the biological products license application for 贝伐单抗玻璃体腔内注射液 , supporting a potential first-mover position in a wAMD-focused bevacizumab filing.In the US, FDA approved the new drug investigational application for 环孢素眼用凝胶 to start a Phase III trial, which could strengthen partnering options and broaden the addressable market beyond Greater China.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Zhaoke Ophthalmology Ltd. published the original content used to generate this news brief via IIS, the Issuer Informat","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"ab6e84fb0542480d9cf75cb6a9fe5601","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260325:nNDL94t3zx:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1191","BK1574","06622","BK1583","BK1587"],"gpt_icon":0},{"id":"2622078523","title":"歸創通橋(02190)3月25日耗資約189.24萬港元回購7.9萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2622078523","media":"智通财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2622078523?lang=zh_tw&edition=fundamental","pubTime":"2026-03-25 19:34","pubTimestamp":1774438449,"startTime":"0","endTime":"0","summary":"智通财经APP讯，归创通桥(02190)公布，2026年3月25日耗资约189.24万港元回购7.9万股股份。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1418913.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1583","02190","BK1100","BK1587","BK1574"],"gpt_icon":0}],"pageSize":20,"totalPage":15,"pageCount":1,"totalSize":293,"code":"91000000","status":"200"}]}}